Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 2Phase 2 1

Status

Completed 6Terminated 2Active not recruiting 2Withdrawn 1Recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1CNS 1Breast 1

Conditions

Recurrence 1Lymphoma 1Leukemia 1Disease 1Central Nervous System Neoplasms 1Breast Neoplasms 1

Interventions

pembrolizumab 70Nivolumab 36Cyclophosphamide 34Carboplatin 28Dexamethasone 23Specimen Handling 22Paclitaxel 22Lenalidomide 22durvalumab 19Radiotherapy 19Gemcitabine 19venetoclax 18Magnetic Resonance Spectroscopy 18Doxorubicin 17Rituximab 16fludarabine 15Ipilimumab 15Bevacizumab 15Cisplatin 14Biopsy 14atezolizumab 13Etoposide 13Vincristine 12Pemetrexed 12belantamab mafodotin 11Docetaxel 11Calcium Dobesilate 11Azacitidine 11olaparib 10Oxaliplatin 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Active not recruiting × neratinib × Clear all
NCT03377387 2026-04-16

Capecitabine 7/7 Schedule With Neratinib in Patients With Metastatic HER2-Positive Breast Cancer

Memorial Sloan Kettering Cancer Center

Phase 1/2 Active not recruiting
34 enrolled
Breast

Breast Neoplasms

NCT02932280 2025-12-05

Safety and Dose Finding Study of Neratinib in Children and Young Adults With Cancer That Has Returned or Not Responded to Treatment

Memorial Sloan Kettering Cancer Center

Phase 1/2 Active not recruiting
14 enrolled
CNSLymphoidOther hematologic neoplasm

Disease, Leukemia, Lymphoma, Recurrence, Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡